← BELITE BIO, INC
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Operating Revenue | — | — | $0 | $0 | $0 | $0 | $0 | |
| Net Interest Income | — | — | $7k |
$49k
+600.00%
|
$3.7m
+7485.71%
|
$6.6m
+78.58%
|
$6.6m
0.00%
|
|
| Research and development | $3.7m | $7.4m | $8.9m | $24.8m | $29.9m | $45.4m | $51.6m | |
| Selling, general and administrative | — | $2.4m | $4.0m | $6.8m | $10.1m | $38.8m | $49.7m | |
| Amortization of Intangible Assets | — | — | — | — | $4k | $12k | — | |
| Operating Expenses | $5.7m | $9.8m | $12.8m | $31.7m | $40.0m | $84.2m | $101.4m | |
| Loss from operations | ($5.7m) |
($9.8m)
-70.59%
|
($12.8m)
-30.87%
|
($31.7m)
-147.00%
|
($40.0m)
-26.30%
|
($84.2m)
-110.54%
|
— | |
| Operating Income (Loss) | ($5.7m) |
($9.8m)
-70.59%
|
($12.8m)
-30.87%
|
($31.7m)
-147.00%
|
($40.0m)
-26.30%
|
($84.2m)
-110.54%
|
($101.4m)
-20.39%
|
|
| Interest income | $12k | $5k | $23k | $74k | $3.7m | $6.6m | $6.6m | |
| Net Non Operating Interest Income Expense | — | — | $7k | $49k | $3.7m | $6.6m | $6.6m | |
| Other Nonoperating Income (Expense) | — | $126k | $166k | ($4k) | $141k | ($41k) | — | |
| Other income (expense) | — | $126k | $166k | ($4k) | $141k | ($41k) | $4.5m | |
| Interest Expense (non-operating) | $21k | — | $16k | $25k | $20k | $2k | $2k | |
| Total other income, net | ($9k) | $131k | $173k | $45k | $3.9m | $6.6m | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | ($413k) | ($1.1m) | ($1.8m) | ($2.7m) | ($2.6m) | ($90.3m) | |
| Pre-Tax Income | ($5.8m) | ($9.7m) | ($12.6m) | ($31.6m) | ($36.1m) | ($77.6m) | ($90.3m) | |
| Loss before income tax | ($5.8m) | ($9.7m) | ($12.6m) | ($31.6m) | ($36.1m) | ($77.6m) | — | |
| Current Income Tax Expense (Benefit) | $1k | $0 | $0 | $9k | $6k | $0 | $0 | |
| Net loss | ($5.8m) | ($9.7m) | ($12.6m) | ($31.6m) | ($36.1m) | ($77.6m) | — | |
| Net Income From Continuing And Discontinued Operation | ($5.8m) | ($9.7m) | ($12.6m) | ($31.6m) | ($36.1m) | ($77.6m) | ($90.3m) | |
| Earnings Per Share, Basic | ($0.65) | ($1.01) | ($0.63) | ($1.19) | ($1.18) | ($2.31) | ($2.54) | |
| Earnings Per Share, Diluted | ($0.65) | ($1.01) | ($0.63) | ($1.19) | ($1.18) | ($2.31) | ($2.54) | |
| Basic (in shares) | $8.8m | $9.6m | $20.0m | ($1) | ($1) | ($2) | $35.5m | |
| Diluted (in shares) | $8.8m | $9.6m | $20.0m | ($1) | ($1) | ($2) | $35.5m | |
| Weighted Average Number of Shares Outstanding, Basic | — | 9.6m | 20.0m | 26.6m | 30.5m | 33.5m | 35.5m | |
| Basic Average Shares | — | 9.6m | $20.0m | $26.6m | $30.5m | $33.5m | $35.5m | |
| Diluted Average Shares | — | 9.6m | $20.0m | $26.6m | $30.5m | $33.5m | $35.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | 9.6m | 20.0m | 26.6m | 30.5m | 33.5m | 35.5m | |
| Additional Financial Items | ||||||||
| Foreign currency translation adjustments, net of nil tax | $6k | ($152k) | ($196k) | $18k | ($286k) | $124k | — | |
| Diluted EPS | ($0.65) | ($1.01) | ($0.63) | ($1.19) | ($1.18) | ($2.31) | ($2.54) | |
| Diluted NI Availto Com Stockholders | ($5.8m) | ($9.7m) | ($12.6m) | ($31.6m) | ($36.1m) | ($77.6m) | ($90.3m) | |
| Normalized EBITDA | — | — | ($12.4m) | ($31.2m) | ($35.7m) | ($77.1m) | ($94.8m) | |
| Normalized Income | ($5.8m) | ($9.7m) | ($12.6m) | ($31.6m) | ($36.1m) | ($77.6m) | ($90.3m) | |
| Other Gand A | — | $2.4m | $4.0m | $6.8m | $10.1m | $38.8m | — | |
| Reconciled Depreciation | — | — | $198k | $399k | $449k | $464k | $464k | |
| Tax Effect Of Unusual Items | — | — | $0 | $0 | $0 | $0 | $0 | |
| Tax Provision | $1k | $0 | $0 | $9k | $6k | $0 | $0 | |
| Tax Rate For Calcs | — | — | $0 | $0 | $0 | $0 | $0 | |
| Total comprehensive loss | ($5.7m) | ($9.8m) | ($12.8m) | ($31.6m) | ($36.4m) | ($77.5m) | — | |
| Total Expenses | $5.7m | $9.8m | $12.8m | $31.7m | $40.0m | $84.2m | $101.4m |